| TA组(n = 10) | BEL组(n = 10) | 常规治疗组(n = 10) | F/χ2 | P | ||||
SLEDAI-2000 | 13.3 ± 1.1 | 12.8 ± 1.4 | 13.1 ± 1.1 | 0.443 | 0.647 | ||||
ACA-IgG (GPLU/mL) | 110.32 ± 5.3 | 111.69 ± 6.2 | 108.49 ± 6.6 | 0.704 | 0.504 | ||||
ACA-IgM (MPLU/mL) | 36.57 ± 2.9 | 34.88 ± 3.7 | 35.68 ± 2.2 | 0.823 | 0.45 | ||||
β2GPI-IgG (AU/mL) | 187.47 ± 8.8 | 184.52 ± 8.1 | 189.35 ± 7.0 | 0.925 | 0.409 | ||||
β2GPI-IgM (AU/mL) | 51.11 ± 4.53 | 50 ± 6.16 | 46.1 ± 4.28 | 2.694 | 0.086 | ||||
LA比值 | 1.561 ± 0.07 | 1.529 ± 0.06 | 1.554 ± 0.05 | 0.781 | 0.468 | ||||
外周血BLYS (ng/mL) | 7.80 ± 0.8 | 7.30 ± 1.0 | 7.50 ± 0.6 | 0.823 | 0.45 | ||||
外周血APRIL (ng/mL) | 29.10 ± 6.4 | 27.70 ± 5.6 | 26.60 ± 3.6 | 0.549 | 0.584 | ||||
B细胞绝对值(/uL) | 329.28 ± 30.3 | 334.95 ± 50.6 | 365.43 ± 111.4 | 0.714 | 0.499 | ||||
T细胞绝对值(/uL) | 1116.16 ± 470.91 | 1108.19 ± 435.48 | 1290.23 ± 518.76 | 0.467 | 0.632 | ||||